Panjon Past Earnings Performance
Past criteria checks 2/6
Panjon has been growing earnings at an average annual rate of 23.4%, while the Pharmaceuticals industry saw earnings growing at 17% annually. Revenues have been declining at an average rate of 19.9% per year. Panjon's return on equity is 1.1%, and it has net margins of 1.3%.
Key information
23.4%
Earnings growth rate
-19.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -19.9% |
| Return on equity | 1.1% |
| Net Margin | 1.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Panjon makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 126 | 2 | 12 | 0 |
| 31 Dec 23 | 86 | 8 | 18 | 0 |
| 30 Sep 23 | 52 | 8 | 18 | 0 |
| 30 Jun 23 | 58 | 1 | 6 | 0 |
| 31 Mar 23 | 61 | 8 | 17 | 0 |
| 31 Dec 22 | 61 | -42 | 16 | 0 |
| 30 Sep 22 | 83 | -41 | 17 | 0 |
| 30 Jun 22 | 82 | -42 | 15 | 0 |
| 31 Mar 22 | 84 | -42 | 15 | 0 |
| 31 Dec 21 | 113 | 2 | 9 | 0 |
| 30 Sep 21 | 118 | 1 | 9 | 0 |
| 30 Jun 21 | 132 | 1 | 9 | 0 |
| 31 Mar 21 | 145 | 1 | 8 | 0 |
| 31 Mar 18 | 201 | 1 | 4 | 0 |
| 31 Mar 17 | 140 | 1 | 5 | 0 |
| 31 Mar 16 | 123 | 4 | 6 | 0 |
| 31 Dec 15 | 179 | -33 | 5 | 0 |
| 30 Sep 15 | 196 | -32 | 4 | 0 |
| 30 Jun 15 | 191 | -32 | 3 | 0 |
| 31 Mar 15 | 195 | -34 | 6 | 0 |
| 31 Dec 14 | 191 | -3 | 11 | 0 |
| 30 Sep 14 | 201 | 2 | 0 | 0 |
| 30 Jun 14 | 205 | 2 | 0 | 0 |
| 31 Mar 14 | 193 | -2 | 11 | 0 |
| 31 Dec 13 | 178 | 3 | 28 | 0 |
| 30 Sep 13 | 164 | 1 | 28 | 0 |
| 30 Jun 13 | 181 | 1 | 28 | 0 |
Quality Earnings: 526345 has high quality earnings.
Growing Profit Margin: 526345's current net profit margins (1.3%) are lower than last year (13.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 526345 has become profitable over the past 5 years.
Accelerating Growth: 526345's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 526345 had negative earnings growth (-80.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18%).
Return on Equity
High ROE: 526345's Return on Equity (1.1%) is considered low.